Pharmazell

Photo
19.04.2022 • News

Novasep and PharmaZell Conclude Merger

Following exclusive negotiations that started last September, German API specialist PharmaZell and French CDMO Novasep have merged as of Apr. 7. The combined group will have revenues of nearly €500 million and employ more than 2,000 people across 10 production and R&D sites – seven in Europe, two in India and one in the US.

Photo
23.09.2021 • News

Pharmazell and Novasep in Exclusive Merger Talks

German API specialist PharmaZell and French CDMO Novasep are in exclusive talks about a merger that the companies say would create a leading European platform in the attractive API manufacturing and CDMO space with a complementary set of differentiated technologies and highly diversified base of blue-chip pharma and biotech customers.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.